Volume 3.44 | Nov 10

Mammary Cell News 3.44, November 10, 2011
     In this issue: Publications | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter
Twist Contributes to Hormone Resistance in Breast Cancer by Downregulating Estrogen Receptor-α
In this study, researchers identified the oncogenic protein, TWIST1 (Twist), which is overexpressed in high-grade breast cancers, as a potential negative regulator of estrogen receptor expression. [Oncogene]
Abstract | Press Release

New Podcast: ALDH in Breast Cancer Treatment Response
PUBLICATIONS (Ranked by Impact Factor of the Journal)


Synergistic Antitumor Activity of Lapatinib and Retinoids on a Novel Subtype of Breast Cancer with Coamplification of ERBB2 and RARA
Here, researchers demonstrate that 23–32% of the human ERBB2+ breast cancers show coamplification of retinoic acid receptor alpha (RARA), encoding the retinoic acid receptor, RARα. [Oncogene] Abstract

Trastuzumab Induces Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) in HER-2-Non-Amplified Breast Cancer Cell Lines
In this study, researchers investigated the possibility that trastuzumab might induce ADCC against HER-2-non-amplified breast cancer cells. [Ann Oncol] Abstract

High Level of miR-21, miR-10b, and miR-31 Expression in Bilateral vs. Unilateral Breast Carcinomas
This study suggests that bilateral breast tumors have somewhat distinct patterns of molecular events as compared to the unilateral disease. [Breast Cancer Res Treat] Abstract

ERp29 Induces Breast Cancer Cell Growth Arrest and Survival through Modulation of Activation of p38 and Upregulation of ER Stress Protein p58IPK
Here, scientists show that endoplasmic reticulum protein 29 (ERp29)-induced cancer cell growth arrest is modulated by the interplay between the concomitant phosphorylation of p38 and upregulation of the inhibitor of the interferon-induced, double-stranded RNA-activated protein kinase, p58IPK. [Lab Invest] Abstract

Regulation of CXCL8/IL-8 Expression by Zonula Occludens-1 in Human Breast Cancer Cells
Researchers investigated here the influence of zonula occludens-1 on chemokines expression in breast cancer cells. [Mol Cancer Res] Abstract

MYC Gene Amplification Is Often Acquired in Lethal Distant Breast Cancer Metastases of Unamplified Primary Tumors
Researchers’ observations underscore the importance of MYC in breast cancer progression/metastasis, as well as its relevance as a potential therapeutic target in otherwise incurable metastatic disease. [Mod Pathol] Abstract

Mammary Tumors that Become Independent of the Type I Insulin-Like Growth Factor Receptor Express Elevated Levels of Platelet-Derived Growth Factor Receptors
These results demonstrate a novel interaction between the insulin-like growth factor receptor and platelet-derived growth factor receptors and highlight an important, therapeutically relevant pathway, for tumor cell migration and invasion. [BMC Cancer] Abstract

TBX3 Over-Expression Causes Mammary Gland Hyperplasia and Increases Mammary Stem-Like Cells in an Inducible Transgenic Mouse Model
In this study, researchers created doxycycline inducible double transgenic mice (MMTV-rtTA;tet-myc-TBX3-IRES-Luciferase) to test whether T-box transcription factor TBX3 over-expression can induce tumor formation within the mammary gland. [BMC Dev Biol] Abstract


RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination with Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
This phase III study compared the efficacy and safety of bevacizumab combined with standard chemotherapy regimens versus chemotherapy alone as second-line treatment of patients with human epidermal growth factor receptor 2–negative metastatic breast cancer. [J Clin Oncol] Abstract

A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer
This study was conducted to obtain preliminary evidence of clinical response in metastatic breast and ovarian cancer patients. [Clin Cancer Res] Abstract | Press Release

Early Operable Breast Cancer in Elderly Women Treated with an Aromatase Inhibitor Letrozole as Sole Therapy
Scientists studied the outcome of patients treated with letrozole as primary endocrine therapy. [Br J Cancer] Abstract

CHEK2*1100delC Homozygosity Is Associated with a High Breast Cancer Risk in Women
This study investigated the occurrence of homozygosity for the CHEK2*1100delC allele among familial breast cancer cases and the associated breast cancer risk. [J Med Genet] Abstract

View Nature.com Webcast: Current Controversies - HIV Vaccines

First Evidence of New ‘Druggable’ DNA Repair Target to Destroy Cancer Cells
Researchers have developed small molecules that block APE1. They tested the ability of these molecules to stop the enzyme from repairing DNA damage in breast, pancreatic and cervical cancer cells containing faults in BRCA1 or BRCA2 genes. [Press release from Cancer Research UK discussing research presented at the National Cancer Research Institute Cancer Conference, Liverpool] Press Release

UT Arlington Researchers Receive $1.2 Million for Cancer Research
The Cancer Prevention & Research Institute of Texas has awarded two University of Texas (UT) at Arlington bioengineering researchers more than $1.2 million to explore better methods of detecting cancer. [University of Texas at Arlington] Press Release

Duncan Cancer Center Researchers Awarded $13 Million in New Round of CPRIT Grants
Researchers in the NCI-designated Dan L. Duncan Cancer Center at Baylor College of Medicine have received an additional $13 million in the new round of grants announced by the Cancer Prevention Research Institute of Texas. [Baylor College of Medicine] Press Release

Breast Cancer Drug Not Proven to be Better Than Existing Treatments, Says Draft Guidance
In its latest draft guidance, the National Institute for Health and Clinical Excellence intends to advise the NHS against routinely prescribing a drug that can be used to delay the growth of a particular type of breast cancer. [National Institute for Health and Clinical Excellence, United Kingdom] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 7th Annual Stem Cell Summit 
February 21, 2012 
New York, United States

our events page to see a complete list of events in the mammary cell community.

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Research and Development Technologist, hPSC Media (STEMCELL Technologies)

Lab Technologist – Pluripotent Stem Cells (STEMCELL Technologies)

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Postdoctoral Training Fellow, Molecular Pathology Team (The Institute of Cancer Research)

Postdoctoral Fellow in Breast Cancer (Indiana University School of Medicine)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected]m with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us